ONVO - Organovo Holdings, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Organovo Holdings, Inc.

6275 Nancy Ridge Drive
Suite 110
San Diego, CA 92121
United States
858-224-1000
http://www.organovo.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees109

Key Executives

NameTitlePayExercisedYear Born
Mr. Craig Kussman MBAChief Financial Officer352.36kN/A1959
Dr. Sharon Collins Presnell Ph.D.Chief Scientific Officer479.56kN/A1969
Ms. Jennifer Kinsbruner Bush J.D.Sr. VP, Gen. Counsel, Corp. Sec. & Compliance Officer472.58kN/A1975
Mr. Taylor J. CrouchCEO, Pres & DirectorN/AN/A1960
Steve E. KunszaboVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Organovo Holdings, Inc., an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company offers two commercial products, which include ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing a suite of standardized and 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology, or disease for use in drug discovery and development, and disease modeling; and 3D human tissues for clinical applications, such as therapeutic liver tissue patch. Organovo Holdings, Inc. was founded in 2007 and is headquartered in San Diego, California.

Corporate Governance

Organovo Holdings, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.